Skip to main content

Specialty Pharmacy

  • Actavis to acquire Forest Labs. for approximately $25 billion

    DUBLIN — Actavis and Forest Labs. on Tuesday announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion, or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock). The per share consideration represents a premium of approximately 25% per share over Forest’s stock price, and a premium of approximately 31% over Forest’s 10-day volume weighted average stock price, as of the close of trading on Feb.

  • Hy-Vee acquires Amber Pharmacy

    WEST DES MOINES, Iowa — Hy-Vee on Monday announced that it has entered into an agreement to purchase Amber Pharmacy, a specialty pharmacy solutions provider based in Omaha, Neb. Hy-Vee and Amber Pharmacy have been partners in Hy-Vee Pharmacy Solutions since 2010. This acquisition allows Hy-Vee to expand its current specialty pharmacy business, providing customers with increased specialty options, access and affordability.

  • Novartis acquires CoStim Pharmaceuticals

    BASEL, Switzerland — Novartis on Monday announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

  • Diplomat Specialty Pharmacy initiates content partnership with NASP

    FLINT, Mich. — Diplomat Specialty Pharmacy on Monday announced that it has initiated a content partnership with the National Association of Specialty Pharmacy.

    The new partnership will support Diplomat’s recently launched web platform, diplomat.is, and its goal to be a leading resource for specialty pharmacy. Additionally, the partnership will further establish NASP’s position as a leading voice in specialty pharmacy and clinical news.

  • Vimizim receives FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration has approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome), which is a rare disease caused by a deficiency in N-acetylgalactosamine-6-sulfate sulfatase (GALNS).

  • Walgreens expands access to Walgreens Connected Care hepatitis C program

    DEERFIELD, Ill. — With new advances in treatment therapy now available for hepatitis C patients, Walgreens on Monday announced it is expanding access to Walgreens Connected Care hepatitis C program through its more than 100 hepatitis C-specialized pharmacies. Walgreens Connected Care is an education and support plan designed to help patients achieve a sustained virologic response and improved quality of life through medication adherence. 

  • Teva's Synribo gets FDA approval

    JERUSALEM — Teva Pharmaceutical Industries on Thursday announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

    The drug is indicated for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

  • Janssen Biotech: Second indication won for cancer drug Imbruvica

    HORSHAM, Pa. — Janssen Biotech on Wednesday announced the Food and Drug Administration has approved Imbruvica (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Imbruvica was first approved in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Both indications are based on an overall response rate. An improvement in survival or disease-related symptoms has not been established.

X
This ad will auto-close in 10 seconds